ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
Monday, February 26, 2024
Uris
Oncology
ImmuneOnco is a HongKong stock exchange-listed, clinical stage biotech company focused on discovering and developing immunotherapies to treat cancer.
The most advanced clinical program is timdarpacept (IMM01), an SIRPα-IgG1 Fc with ADCC/ADCP inducing activity. It is going to enter phase III in 2024 with the planned BLA submission in 2025 to treat higher-risk myelodysplastic syndromes (HR-MDS) and R/R classic Hodgkin lymphoma (cHL). Timdarpacept in combination with azacitidine to treat chronic myelomonocytic leukemia (CMML) was approved by FDA for Orphan Drug Designation.
Other clinical stage assets include VEGFxPD-L1, PD-L1xCD47, CD47xCD20, CD47xHER2 (Fast Track designation by FDA), ADCC-enhanced CTLA-4 mAb, CD24 mAb, CD70 mAb etc.
Country
China
Website
http://www.immuneonco.com/
CEO/Top Company Official
Wenzhi Tian
Lead Product in Development
Timdarpacept (IMM01), an SIRPα-IgG1 Fc with ADCC/ADCP-inducing activity. It is going to enter phase III in 2024 with the planned BLA submission in 2025 to treat higher-risk myelodysplastic syndromes (HR-MDS) and R/R classic Hodgkin lymphoma (cHL). Timdarpacept in combination with azacitidine to treat chronic myelomonocytic leukemia (CMML) was approved by FDA for Orphan Drug Designation.
Development Phase of Primary Product
Phase II
Number Of Unlicensed Products
10+
)
){kind=logo}
){kind=logo}
){kind=logo}
)
){kind=logo}
){kind=logo}
){kind=logo}
){kind=logo}
)
)
){kind=logo}
){kind=logo}
){kind=logo}
)
)
)
){kind=logo}